Table 2. Clinical Annotations Corresponding to Patient Mutation Statusa.
| Patient | Status | EGFR Amplification | EGFRvIII | MGMT Methylation |
|---|---|---|---|---|
| P-1 | Glioblastoma | Negative | Negative | Positive |
| P-2 | Glioblastoma | Negative | ND | Negative |
| P-3 | Glioblastoma | ND | ND | ND |
| P-4 | Glioblastoma | Positive | Positive | Positive |
| P-5 | Glioblastoma | Negative | ND | Negative |
| P-6 | Glioblastoma | Negative | Negative | Negative |
| P-7 | Glioblastoma | Positive | Positive | Negative |
| P-8 | Glioblastoma | Positive | Negative | Negative |
| P-9 | Glioblastoma | Positive | Positive | Negative |
| P-10 | Glioblastoma | Negative | ND | Negative |
| P-11 | Glioblastoma | ND | ND | ND |
| P-12 | Glioblastoma | ND | ND | ND |
| H-1 | Healthy | – | – | – |
| H-2 | Healthy | – | – | – |
| H-3 | Healthy | – | – | – |
| H-4 | Healthy | – | – | – |
| H-5 | Healthy | – | – | – |
| H-6 | Healthy | – | – | – |
| H-7 | Healthy | – | – | – |
| H-8 | Healthy | – | – | – |
a
Clinical pathology results of the patient diagnosed with GBM. *ND = not determined. EGFR amplification, EGFRvIII and MGMT methylation status was determined by sequencing of the primary tumor.